Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None20222021202020192018201720162015201420132012201120102009200820072006 Date Title 10/11/21 Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne 10/4/21 Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio 10/4/21 Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy 9/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/27/21 Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA 9/14/21 Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress 9/7/21 Sarepta Therapeutics to Present at Upcoming Investor Conferences 9/7/21 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program 8/31/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8/4/21 Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 31 - 40 of 726 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None20222021202020192018201720162015201420132012201120102009200820072006 Date Title 10/11/21 Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne 10/4/21 Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio 10/4/21 Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy 9/30/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/27/21 Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA 9/14/21 Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress 9/7/21 Sarepta Therapeutics to Present at Upcoming Investor Conferences 9/7/21 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program 8/31/21 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8/4/21 Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 31 - 40 of 726